Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of prostate adenocarcinoma (a specific type of prostate cancer), not including a type called small cell.
• People whose prostate cancer has gotten worse, and who have had hormone-suppressing treatment (ADT) or surgical removal of the testicles within the 6 months before screening.
• People whose cancer has shown signs of progressing after stopping certain older anti-hormone medications (with specific waiting periods depending on which medication was used — confirm timing with trial site).
• People who have evidence that the cancer has spread to other parts of the body (metastatic disease).
• People who have previously been treated with 1 or 2 newer hormone-blocking medications for prostate cancer (at any stage), and whose cancer has continued to grow during or after that treatment.
• People taking bone-strengthening medications (such as bisphosphonates or denosumab) who have been on a stable dose for more than 4 weeks before joining the trial.
• People who had side effects from previous cancer treatments must have largely recovered before joining.
• People living with HIV, provided the HIV is well controlled on treatment.
• People who have Hepatitis B must have been on antiviral treatment for at least 4 weeks and have an undetectable level of the virus in their blood.
• People with a history of Hepatitis C infection, provided the virus is no longer detectable in their blood.

Who may not be able to join:

• People with a history of problems with the pituitary gland.
• People with poorly controlled diabetes.
• People with serious or unstable heart or blood vessel conditions, including recent stroke, mini-stroke, or heart attack within 6 months, severe heart failure, symptomatic coronary heart disease, or unstable chest pain.
• People with a personal or family history of a heart rhythm condition involving a prolonged QT interval (an electrical problem in the heart).
• People with certain blood or bone marrow disorders (MDS or AML), or signs suggesting these conditions.
• People with a history of, or current, adrenal gland insufficiency (where the adrenal glands don't produce enough hormones).
• People who have had lung inflammation (not caused by infection) that required steroid treatment, or who currently have lung inflammation.
• People living with HIV who have also had Kaposi's sarcoma or a condition called Multicentric Castleman's Disease.
• People who have had major surgery (including certain prostate procedures, but not prostate biopsy) within 28 days before joining, and have not yet fully recovered.
• People on an unstable dose of thyroid hormone medication within 6 months before the first dose.
• People who received a whole blood transfusion within the 120 days before joining (certain other blood product transfusions may be acceptable — confirm with trial site).
• People who have received other systemic cancer treatments or experimental therapies within 4 weeks before joining.
• People who have received radiotherapy within 2 weeks of starting the trial, or who still have side effects from radiation requiring steroid treatment.
• People who have received a live or weakened-live vaccine within 30 days before the first dose (non-live vaccines are generally acceptable).
• People with a known immune system deficiency, or who have been taking steroid or immune-suppressing medications within 7 days before the first dose.
• People who have or have had another cancer (besides prostate cancer) that is still active or required treatment within the past 3 years.
• People with active cancer spread to the brain or spinal fluid.
• People with an active autoimmune disease that has needed systemic treatment within the past 2 years.
• People with an active infection that requires systemic treatment.
• People with active, ongoing Hepatitis B or Hepatitis C infection.

Important: Always verify eligibility with the trial site directly before applying.